The stock of Pulmonx Corp (LUNG) has seen a 27.47% increase in the past week, with a 17.04% gain in the past month, and a -34.88% decrease in the past quarter. The volatility ratio for the week is 4.55%, and the volatility levels for the past 30 days are at 4.57% for LUNG. The simple moving average for the last 20 days is 20.17% for LUNG’s stock, with a simple moving average of -13.44% for the last 200 days.
Is It Worth Investing in Pulmonx Corp (NASDAQ: LUNG) Right Now?
Company’s 36-month beta value is 0.66.Analysts have differing opinions on the stock, with 0 analysts rating it as a “buy,” 0 as “overweight,” 0 as “hold,” and 0 as “sell.”
The public float for LUNG is 34.95M, and currently, short sellers hold a 4.94% ratio of that floaft. The average trading volume of LUNG on May 02, 2024 was 595.75K shares.
LUNG) stock’s latest price update
Pulmonx Corp (NASDAQ: LUNG)’s stock price has gone rise by 20.53 in comparison to its previous close of 7.72, however, the company has experienced a 27.47% increase in its stock price over the last five trading days. Seeking Alpha reported 2024-05-01 that Pulmonx Corporation (NASDAQ:LUNG ) Q1 2024 Earnings Call Transcript May 1, 2024 4:30 PM ET Company Participants Elizabeth Sparicio – Investor Relations at the Gilmartin Group Steve Williamson – President & Chief Executive Officer Mehul Joshi – Chief Financial Officer Conference Call Participants Jon Young – Canaccord Rick Wise – Stifel Vik Chopra – Wells Fargo Operator Good day, and thank you for standing by. Welcome to Pulmonx Q1 2024 Earnings Conference Call.
Analysts’ Opinion of LUNG
Many brokerage firms have already submitted their reports for LUNG stocks, with Wells Fargo repeating the rating for LUNG by listing it as a “Equal Weight.” The predicted price for LUNG in the upcoming period, according to Wells Fargo is $14 based on the research report published on February 23, 2024 of the current year 2024.
Craig Hallum, on the other hand, stated in their research note that they expect to see LUNG reach a price target of $18. The rating they have provided for LUNG stocks is “Buy” according to the report published on September 05th, 2023.
Wells Fargo gave a rating of “Overweight” to LUNG, setting the target price at $15 in the report published on February 27th of the previous year.
LUNG Trading at 6.29% from the 50-Day Moving Average
After a stumble in the market that brought LUNG to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -37.28% of loss for the given period.
Volatility was left at 4.57%, however, over the last 30 days, the volatility rate increased by 4.55%, as shares surge +17.68% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -36.21% lower at present.
During the last 5 trading sessions, LUNG rose by +26.71%, which changed the moving average for the period of 200-days by -29.60% in comparison to the 20-day moving average, which settled at $7.81. In addition, Pulmonx Corp saw -27.02% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at LUNG starting from Rose Geoffrey Beran, who sale 1,184 shares at the price of $7.49 back on Apr 22 ’24. After this action, Rose Geoffrey Beran now owns 306,684 shares of Pulmonx Corp, valued at $8,868 using the latest closing price.
Rose Geoffrey Beran, the CHIEF COMMERCIAL OFFICER of Pulmonx Corp, sale 1,184 shares at $9.36 during a trade that took place back on Mar 22 ’24, which means that Rose Geoffrey Beran is holding 307,868 shares at $11,082 based on the most recent closing price.
Stock Fundamentals for LUNG
Current profitability levels for the company are sitting at:
- -0.82 for the present operating margin
- 0.74 for the gross margin
The net margin for Pulmonx Corp stands at -0.8. The total capital return value is set at -0.42. Equity return is now at value -46.17, with -32.11 for asset returns.
Based on Pulmonx Corp (LUNG), the company’s capital structure generated 0.26 points at debt to capital in total, while cash flow to debt ratio is standing at -0.66. The debt to equity ratio resting at 0.34. The interest coverage ratio of the stock is -22.57.
Currently, EBITDA for the company is -59.99 million with net debt to EBITDA at 0.57. When we switch over and look at the enterprise to sales, we see a ratio of 4.49. The receivables turnover for the company is 6.94for trailing twelve months and the total asset turnover is 0.44. The liquidity ratio also appears to be rather interesting for investors as it stands at 6.95.
Conclusion
In a nutshell, Pulmonx Corp (LUNG) has experienced a mixed performance in recent times. The stock has received mixed “buy” and “hold” ratings from analysts. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
